StreetInsider.com News Articles http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 07 Jul 2026 08:36:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects <span value="Bombay:543635" idsrc="xmltag.org" >Piramal Pharma's</span> continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Piramal+Pharma%27s+FY2026+Annual+Report+showcases+global+scale%2C+innovation-led+growth+and+sustainability+milestones/26739256.html Tue, 07 Jul 2026 08:36:00 -0400 543635 543635 A.06822034 A.29047413 A.38567343 O.01402385 O.20026344 O.29322678 O.47558727 PPLPHARMA. PPLPHARMA. Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits http://www.streetinsider.com/Press+Releases/Piramal+Pharma+Solutions+Highlights+Strong+Performance+Across+More+Than+200+Customer+Audits/26669089.html <div class="xn-content"> <ul type="disc"><li><i>Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes.</i></li><li><i>This milestone reflects the Company's long-range quality strategy focused on sustained compliance, continuous audit readiness, and operational effectiveness.</i></li><li><i>Through robust governance, quality culture initiatives, workforce development, and digital transformation, Piramal continues to strengthen its position as a reliable global CDMO partner.</i></li></ul><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>June 22, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:2904741373" idsrc="xmltag.org" >Piramal Pharma Solutions</span> ("PPS"), a leading global <span>Contract Development and Manufacturing Organization</span> (CDMO) and part of <span http://www.streetinsider.com/Press+Releases/Piramal+Pharma+Solutions+Highlights+Strong+Performance+Across+More+Than+200+Customer+Audits/26669089.html Mon, 22 Jun 2026 04:46:00 -0400 543635 543635 A.29047413 A.50216776 O.29322678 O.45123250 O.47558727 PPLPHARMA PPLPHARMA. PPLPHARMA. Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits http://www.streetinsider.com/Press+Releases/Piramal+Pharma+Solutions+Highlights+Strong+Performance+Across+More+Than+200+Customer+Audits/26669089.html <div class="xn-content"> <ul type="disc"><li><i>Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes.</i></li><li><i>This milestone reflects the Company's long-range quality strategy focused on sustained compliance, continuous audit readiness, and operational effectiveness.</i></li><li><i>Through robust governance, quality culture initiatives, workforce development, and digital transformation, Piramal continues to strengthen its position as a reliable global CDMO partner.</i></li></ul><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>June 22, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:2904741373" idsrc="xmltag.org" >Piramal Pharma Solutions</span> ("PPS"), a leading global <span>Contract Development and Manufacturing Organization</span> (CDMO) and part of <span http://www.streetinsider.com/Press+Releases/Piramal+Pharma+Solutions+Highlights+Strong+Performance+Across+More+Than+200+Customer+Audits/26669089.html Mon, 22 Jun 2026 04:46:00 -0400 543635 543635 A.29047413 A.50216776 O.29322678 O.45123250 O.47558727 PPLPHARMA PPLPHARMA. PPLPHARMA. Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits http://www.streetinsider.com/Press+Releases/Piramal+Pharma+Solutions+Highlights+Strong+Performance+Across+More+Than+200+Customer+Audits/26669089.html <div class="xn-content"> <ul type="disc"><li><i>Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes.</i></li><li><i>This milestone reflects the Company's long-range quality strategy focused on sustained compliance, continuous audit readiness, and operational effectiveness.</i></li><li><i>Through robust governance, quality culture initiatives, workforce development, and digital transformation, Piramal continues to strengthen its position as a reliable global CDMO partner.</i></li></ul><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location></span>, <span class="legendSpanClass"><chron>June 22, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:2904741373" idsrc="xmltag.org" >Piramal Pharma Solutions</span> ("PPS"), a leading global <span>Contract Development and Manufacturing Organization</span> (CDMO) and part of <span http://www.streetinsider.com/Press+Releases/Piramal+Pharma+Solutions+Highlights+Strong+Performance+Across+More+Than+200+Customer+Audits/26669089.html Mon, 22 Jun 2026 04:46:00 -0400 543635 543635 A.29047413 A.50216776 O.29322678 O.45123250 O.47558727 PPLPHARMA PPLPHARMA. PPLPHARMA.